At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Court revives lawsuit against Pfizer's diversity fellowship Group claims Pfizer program discriminates against white, Asian-American applicants Pfizer defends diversity efforts, lawsuit follows ...

Now, Pfizer and the trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) rank among the organizations that have helped Trump raise a record-setting $150 million in pledges ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.

Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...

Pfizer CEO met RFK Jr. and Trump, developed good relationship Trump committed to reforming pharmacy benefit managers, reducing medicine costs Pfizer faces investor pressure over strategy, shares ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...

Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its supply chain, according to press reports. The big pharma has said in recent weeks that it ...

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of investors, aiming to add eight ...